In the last trading session, 2.85 million shares of the Seres Therapeutics Inc (NASDAQ:MCRB) were traded, and its beta was 2.83. Most recently the company’s share price was $0.46, and it changed around -$0.2 or -30.35% from the last close, which brings the market valuation of the company to $80.55M. MCRB currently trades at a discount to its 52-week high of $1.53, offering almost -232.61% off that amount. We note from Seres Therapeutics Inc’s average daily trading volume that its 10-day average is 1.35 million shares, with the 3-month average coming to 1.26 million.
Seres Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.20. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended MCRB as a Hold, whereas 4 deemed it a Buy, and 2 rated it as Underweight. Seres Therapeutics Inc is expected to report earnings per share of 0.08 for the current quarter.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Instantly MCRB has showed a red trend with a performance of -30.35% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.6700 on recent trading dayincreased the stock’s daily price by 31.34%. The company’s shares are currently down -44.40% year-to-date, but still down -11.17% over the last five days. On the other hand, Seres Therapeutics Inc (NASDAQ:MCRB) is -37.39% down in the 30-day period. We can see from the shorts that 16.01 million shares have been sold at a short interest cover period of 18.65 day(s).
The consensus price target as assigned by Wall Street analysts is $1.25, which translates to bulls needing to increase their stock price by 63.2% from its current value. Analyst projections state that MCRB is forecast to be at a low of $1.25 and a high of $1.25.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 10M in revenue for the current quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 5.33%.
MCRB Dividends
Seres Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-12.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 13.02% of Seres Therapeutics Inc shares, and 36.18% of them are in the hands of institutional investors. The stock currently has a share float of 41.60%. Seres Therapeutics Inc stock is held by 79.0 institutions, with FLAGSHIP PIONEERING INC. being the largest institutional investor. By 2024-06-30, it held 15.2573% of the shares, which is about 23.12 million shares worth $16.73 million.
FMR LLC, with 14.9934% or 22.72 million shares worth $16.44 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Feb 28, 2025 . The former held 6.79 shares worth $3.14 million, making up 3.90% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 3.86 shares worth around $1.78 million, which represents about 2.21% of the total shares outstanding.
